Kevin Sayer Sells 26,756 Shares of DexCom (NASDAQ:DXCM) Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,756 shares of DexCom stock in a transaction on Monday, July 6th. The stock was sold at an average price of $72.00, for a total transaction of $1,926,432.00. Following the completion of the transaction, the insider directly owned 355,726 shares of the company’s stock, valued at $25,612,272. The trade was a 7.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Up 0.7%

Shares of NASDAQ DXCM opened at $74.06 on Thursday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $89.98. The firm’s 50-day moving average price is $68.99 and its 200-day moving average price is $68.34. The stock has a market capitalization of $28.58 billion, a price-to-earnings ratio of 31.65, a P/E/G ratio of 1.21 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the firm posted $0.32 earnings per share. The firm’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, equities research analysts anticipate that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on DXCM shares. UBS Group set a $95.00 price target on DexCom in a research report on Wednesday, June 10th. Benchmark reiterated a “buy” rating on shares of DexCom in a research report on Tuesday, June 23rd. Mizuho set a $85.00 target price on shares of DexCom and gave the company an “outperform” rating in a research note on Tuesday, June 9th. Stifel Nicolaus set a $90.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Friday, June 5th. Finally, Canaccord Genuity Group set a $82.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $84.88.

Hedge Funds Weigh In On DexCom

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its position in shares of DexCom by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company’s stock worth $727,842,000 after purchasing an additional 42,411 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of DexCom by 6.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,999,057 shares of the medical device company’s stock valued at $530,897,000 after purchasing an additional 516,526 shares during the period. Norges Bank bought a new position in shares of DexCom in the fourth quarter worth about $483,356,000. Invesco Ltd. grew its holdings in shares of DexCom by 14.8% in the fourth quarter. Invesco Ltd. now owns 5,315,367 shares of the medical device company’s stock worth $352,781,000 after purchasing an additional 686,228 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in DexCom by 7.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 3,128,114 shares of the medical device company’s stock worth $207,613,000 after buying an additional 220,313 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.